Connecting clinical care, data and research
PartnershipsContact
← Back to publications

RESEARCH PUBLICATION / 2025

Original Article

DPP-4 inhibitors and tuberculosis risk: Nationwide target trial emulation

Target trial emulation of DPP-4 Inhibitors in patients with T2DM for pulmonary tuberculosis: a nationwide observational data.

BMC Medicine

Citation & Authors

BMC Med. 2025;23(1):587.

Yi-Geng Chen; James Cheng-Chung Wei; Fu-Shun Yen; Chen-Yu Sung; Yu-Han Huang; Teng-Shun Yu; Fuu-Jen Tsai; Chii-Min Hwu; Chih-Cheng Hsu

ABSTRACT · RESEARCH SUMMARY

Research summary

This Taiwanese National Health Insurance study matched 328,842 pairs of patients with type 2 diabetes. Incident pulmonary tuberculosis rates were 1.93 per 1,000 person-years in DPP-4 inhibitor users and 2.18 in nonusers; the adjusted HR was 0.85 (95% CI 0.81–0.90). Longer cumulative treatment was associated with lower risk, but the observational design and time-related biases must be considered.

Key points based on the public abstract; this is a reading guide, not a full abstract translation.Read original abstract ↗